Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Myeloma Crowd Radio: Dr. Jacob Laubach, MD, MPP, Dana Farber Cancer Institute

  • Broadcast in Health
  • 0 comments
Myeloma Crowd Radio

Myeloma Crowd Radio

×  

Follow This Show

If you liked this show, you should follow Myeloma Crowd Radio.
h:539173
s:8832811
archived

While immunotherapy approaches expand, proteasome inhibitors remain a staple therapy of multiple myeloma. Learn why they work, how they differ, how the new oral version (Ninlaro) is bringing greater convenience to the clinic, why they continue to be developed and how they are being used in quad combinations with immunotherapies to fight myeloma. Dr. Jacob Laubach shares how they differ, who they work best for (and don't), when they should be used as maintenance therapy and how a new gene may give us clues into who will respond and who will not. 

Thanks to our episode sponsor, Takeda Oncology. 

Comments

 comments